63 related articles for article (PubMed ID: 25075070)
1. Biologic factors associated with tumor oxygenation are prognostic in patients with stage III esophageal cancer: long-term results.
Rades D; Bajrovic A; Schild SE; Thorns C; Kilic E
Anticancer Res; 2014 Aug; 34(8):4351-5. PubMed ID: 25075070
[TBL] [Abstract][Full Text] [Related]
2. The impact of tumor expression of erythropoietin receptors and erythropoietin on clinical outcome of esophageal cancer patients treated with chemoradiation.
Rades D; Golke H; Schild SE; Kilic E
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):152-9. PubMed ID: 17967510
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of vascular endothelial growth factor and its receptor-1 in patients with esophageal cancer.
Kilic E; Schild SE; Thorns C; Bajrovic A; Rades D
Anticancer Res; 2014 Sep; 34(9):5221-6. PubMed ID: 25202119
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors affecting locally recurrent rectal cancer and clinical significance of hemoglobin.
Rades D; Kuhn H; Schultze J; Homann N; Brandenburg B; Schulte R; Krull A; Schild SE; Dunst J
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1087-93. PubMed ID: 17892921
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer.
Saintigny P; Besse B; Callard P; Vergnaud AC; Czernichow S; Colombat M; Girard P; Validire P; Breau JL; Bernaudin JF; Soria JC
Clin Cancer Res; 2007 Aug; 13(16):4825-31. PubMed ID: 17699861
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of patients with locally advanced squamous cell carcinoma of the head and neck. Impact of tumor cell expression of EPO and EPO-R.
Seibold ND; Schild SE; Gebhard MP; Noack F; Schröder U; Rades D
Strahlenther Onkol; 2013 Jul; 189(7):559-65. PubMed ID: 23700207
[TBL] [Abstract][Full Text] [Related]
7. [Expression of erythropoietin receptor in esophageal carcinoma and its correlation to microvessel density].
Li M; Lu Y; Chen XQ
Ai Zheng; 2008 Jan; 27(1):52-7. PubMed ID: 18184464
[TBL] [Abstract][Full Text] [Related]
8. Radio(chemo)therapy plus resection versus radio(chemo)therapy alone for the treatment of stage III esophageal cancer.
Rades D; Schulte R; Yekebas EF; Homann N; Schild SE; Dunst J
Strahlenther Onkol; 2007 Jan; 183(1):10-6. PubMed ID: 17225940
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer.
Rades D; Stoehr M; Meyners T; Bohlen G; Nadrowitz R; Dunst J; Schild SE; Wroblewski J; Albers D; Schmidt R; Alberti W; Tribius S
Strahlenther Onkol; 2008 Apr; 184(4):198-205. PubMed ID: 18398584
[TBL] [Abstract][Full Text] [Related]
10. Epoetin-alpha during radiotherapy for stage III esophageal carcinoma.
Rades D; Schild SE; Yekebas EF; Job H; Schwarz R; Rudat V
Cancer; 2005 Jun; 103(11):2274-9. PubMed ID: 15852356
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of erythropoietin expression and erythropoietin receptor expression on locoregional control and survival of patients irradiated for stage II/III non-small-cell lung cancer.
Rades D; Setter C; Dahl O; Schild SE; Noack F
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):499-505. PubMed ID: 20646855
[TBL] [Abstract][Full Text] [Related]
12. Esophageal tumor length is independently associated with long-term survival.
Yendamuri S; Swisher SG; Correa AM; Hofstetter W; Ajani JA; Francis A; Maru D; Mehran RJ; Rice DC; Roth JA; Walsh GL; Vaporciyan AA
Cancer; 2009 Feb; 115(3):508-16. PubMed ID: 19117343
[TBL] [Abstract][Full Text] [Related]
13. Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational study.
Rades D; Tribius S; Yekebas EF; Bahrehmand R; Wildfang I; Kilic E; Muellerleile U; Gross E; Schild SE; Alberti W
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):459-65. PubMed ID: 16584851
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in the nonsurgical treatment of esophageal carcinoma with radiotherapy or radiochemotherapy: the importance of pretreatment hemoglobin levels.
Rades D; Schild SE; Bahrehmand R; Zschenker O; Alberti WA; Rudat VR
Cancer; 2005 Apr; 103(8):1740-6. PubMed ID: 15742330
[TBL] [Abstract][Full Text] [Related]
15. Tumor length as a prognostic factor in esophageal malignancy: univariate and multivariate survival analyses.
Griffiths EA; Brummell Z; Gorthi G; Pritchard SA; Welch IM
J Surg Oncol; 2006 Mar; 93(4):258-67. PubMed ID: 16496364
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy.
Nomura M; Shitara K; Kodaira T; Hatooka S; Mizota A; Kondoh C; Yokota T; Takahari D; Ura T; Muro K
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):946-52. PubMed ID: 21362578
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor 2--a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer.
Rades D; Setter C; Dahl O; Schild SE; Noack F
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):442-7. PubMed ID: 20950963
[TBL] [Abstract][Full Text] [Related]
18. Impact of VEGF and VEGF receptor 1 (FLT1) expression on the prognosis of stage III esophageal cancer patients after radiochemotherapy.
Rades D; Golke H; Schild SE; Kilic E
Strahlenther Onkol; 2008 Aug; 184(8):416-20. PubMed ID: 18956519
[TBL] [Abstract][Full Text] [Related]
19. [Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice].
Farzad M; De Luca MC; Rubino G; Pirtoli L; Pepi F; Sebaste L; Ponticelli P; Atzeni G; Maranzano E; Silvano G
Radiol Med; 2001; 102(1-2):72-7. PubMed ID: 11677442
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients.
Durmaz O; Demirkaya M; Sevinir B
Pediatr Hematol Oncol; 2011 Sep; 28(6):461-8. PubMed ID: 21707225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
